Examining a possible association between human papilloma virus (HPV) vaccination and migraine: results of a cohort study in the Netherlands

European Journal of Pediatrics

Volumn 174, Issue 5, 2015, Pages 641-649

  Klooster, T M Schurink van’t ^a   de Ridder, M A J ^b   Kemmeren, J M ^a   van der Lei, J ^b   Dekker, F ^c   Sturkenboom, M ^b   de Melker, H E ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bivalent vaccine; HPV; Human papilloma virus; Migraine; Safety

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADVERSE OUTCOME; ARTICLE; CHILD; COHORT ANALYSIS; FEMALE; HUMAN; INCIDENCE; MALE; MIGRAINE; NETHERLANDS; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; SEX RATIO; VACCINATION; ADVERSE EFFECTS; MIGRAINE DISORDERS; PAPILLOMAVIRUS INFECTIONS;

ADOLESCENT; CHILD; COHORT STUDIES; FEMALE; HUMANS; MALE; MIGRAINE DISORDERS; NETHERLANDS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; VACCINATION;

EID: 84928545937     PISSN: 03406199     EISSN: 14321076     Source Type: Journal    
DOI: 10.1007/s00431-014-2444-x     Document Type: Article

References (32)

1. Arnheim-Dahlstrom L, Pasternak B, Svanstrom H, Sparen P, Hviid A (2013) Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. BMJ (Clinical Research ed) 347:f5906. doi:10.1136/bmj.f5906
2. Bigal ME, Arruda MA (2010) Migraine in the pediatric population—evolving concepts. Headache 50(7):1130–1143. doi:10.1111/j.1526-4610.2010.01717.x
3. Cano A, Palomeras E, Alfonso S, Ortega D, Sanz P, Fossas P (2000) Migraine without aura and migrainous disorder in children; International Headache Society (IHS) and revised IHS criteria. Cephalalgia: Int J Headache 20(7):617–620
4. Cervarix (HPV vaccine): update on UK safety covering the first two years of the HPV immunisation programme. (October 2010) MHRA. http://www.mhra.gov.uk/home/groups/pl-p/documents/websiteresources/con096797.pdf
5. Chao C, Klein NP, Velicer CM, Sy LS, Slezak JM, Takhar H, Ackerson B, Cheetham TC, Hansen J, Deosaransingh K, Emery M, Liaw KL, Jacobsen SJ (2012) Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. J Intern Med 271(2):193–203. doi:10.1111/j.1365-2796.2011.02467.x
6. Crawford NW, Cheng A, Andrews N, Charles PG, Clothier HJ, Day B, Day T, Gates P, Macdonnell R, Roberts L, Rodriguez-Casero V, Wijeratne T, Kiers L (2012) Guillain-Barre syndrome following pandemic (H1N1) 2009 influenza A immunisation in Victoria: a self-controlled case series. Med J Aust 197(10):574–578
7. Dekker F, Dieleman J, Neven AK, Ferrari M, Assendelft W (2013) Preventive treatment for migraine in primary care, a population-based study in the Netherlands. Cephalalgia: Int J Headache 33(14):1170–1178. doi:10.1177/0333102413490343
8. Dutch Health Council (2008) [Vaccination against cervical cancer]. Dutch Health Council,, The Hague
9. Gasparini R, Bonanni P, Levi M, Bechini A, Boccalini S, Tiscione E, Amicizia D, Lai PL, Sulaj K, Patria AG, Panatto D (2011) Safety and tolerability of bivalent HPV vaccine: an Italian post-licensure study. Hum Vaccines 7(Suppl):136–146
10. Gee J, Naleway A, Shui I, Baggs J, Yin R, Li R, Kulldorff M, Lewis E, Fireman B, Daley MF, Klein NP, Weintraub ES (2011) Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the vaccine safety datalink. Vaccine 29(46):8279–8284. doi:10.1016/j.vaccine.2011.08.106
11. GlaxoSmithKline Biologicals package insert and patient information—Cervarix. July 2011
12. Grazzi L, Andrasik F (2010) Headache in young age: classification of primary forms. Neurol Sci: Off J Ital Neurol Soc Ital Soc Clin Neurophys 31(Suppl 1):S77–79. doi:10.1007/s10072-010-0280-y
13. Grol MH, Neven AK, Pijnenborg L, Goudswaard AN (2006) Summary of the practice guideline ‘Headache’ from the Dutch College of General Practitioners. Ned Tijdschr Geneeskd 150(6):305–309
14. Hougaard A, Amin FM, Hauge AW, Ashina M, Olesen J (2013) Provocation of migraine with aura using natural trigger factors. Neurology 80(5):428–431. doi:10.1212/WNL.0b013e31827f0f10
15. The International Classification of Headache Disorders, 3rd edition (beta version) (2013). Cephalalgia: an international journal of headache 33(9):629–808. doi:10.1177/0333102413485658
16. Kemmeren J, van der Lei J, Oomen P, de Melker H, Sturkenboom M (2012) Results of testing the linkage of the vaccination registration Praeventis with the IPCI medical record database in the Netherlands. Pharmacoepidemiol Drug Saf 21(Suppl 3):150
17. Knuistingh Neven A, Dekker F (2004) [Migraine after the NHG standard headache]
18. Launer LJ, Terwindt GM, Ferrari MD (1999) The prevalence and characteristics of migraine in a population-based cohort: the GEM study. Neurology 53(3):537–542
19. Macartney KK, Chiu C, Georgousakis M, Brotherton JM (2013) Safety of human papillomavirus vaccines: a review. Drug Saf: Int J Med Toxicol Drug Experience 36(6):393–412. doi:10.1007/s40264-013-0039-5
20. Martin DO, Austin H (1996) Exact estimates for a rate ratio. Epidemiol (Cambridge, Mass) 7(1):29–33
21. Rondy M, van Lier A, van de Kassteele J, Rust L, de Melker H (2010) Determinants for HPV vaccine uptake in the Netherlands: a multilevel study. Vaccine 28(9):2070–2075. doi:10.1016/j.vaccine.2009.12.042
22. Silberstein SD, Dodick DW (2013) Migraine genetics—a review: part I. Headache 53(8):1207–1217. doi:10.1111/head.12156
23. Silberstein SD, Dodick DW (2013) Migraine genetics: part II. Headache 53(8):1218–1229. doi:10.1111/head.12169
24. Tokars JI, Lewis P, DeStefano F, Wise M, Viray M, Morgan O, Gargiullo P, Vellozzi C (2012) The risk of Guillain-Barre syndrome associated with influenza A (H1N1) 2009 monovalent vaccine and 2009-2010 seasonal influenza vaccines: results from self-controlled analyses. Pharmacoepidemiol Drug Saf 21(5):546–552. doi:10.1002/pds.3220
25. van’t Klooster T, Kemmeren J, Vermeer-de Bondt P, Oostvogels B, Phaff T, de Melker H, van der Maas N (2011) Adverse events following vaccination against human papillomavirus: results of the 2010 campaign in the Netherlands. RIVM
26. van’t Klooster T, Kemmeren J, Vermeer-de Bondt P, Oostvogels B, PHaff T, de Melker H, van der Maas N (2011) Human papillomavirus vaccination catch-up campaign in 2009 for girls born 1993 to 1996 in the Netherlands in 2009: results of the post-marketing safety suveillance. RIVM
27. van’t Klooster T, de Ridder M, Kemmeren J, van der Lei J, Wijga A, Sturkenboom M, de Melker H (2013) Association between HPV-vaccination and migraine. RIVM, Bilthoven
28. van Duijn N, Brouwer H, Gooskens R [Children with headache]. Medisch Contact Nr. 26
29. van Lier A, Oomen P, de Hoogh P, Drijfhout I, Elsinghorst B, Kemmeren J, Conyn-van Spaendonck M, de Melker H (2012) Praeventis, the immunisation register of the Netherlands: a tool to evaluate the National Immunisation Programme. Euro surveillance: bulletin europeen sur les maladies transmissibles. Eur Commun Dis Bull 17(17)
30. Vermeer-de Bondt P, Moorer-Lanser N, PHaff T, Oostvogels B, Wesselo C, van der Maas N (2011) Adverse events in the Netherlands vaccination programme: reports in 2010 and review 1994–2010. RIVM, Bilthoven
31. Vlug AE, van der Lei J, Mosseveld BM, van Wijk MA, van der Linden PD, Sturkenboom MC, van Bemmel JH (1999) Postmarketing surveillance based on electronic patient records: the IPCI project. Methods Inf Med 38(4–5):339–344. doi:10.1267/meth99040339
32. Wijga AH, Kerkhof M, Gehring U, de Jongste JC, Postma DS, Aalberse RC, Wolse AP, Koppelman GH, van Rossem L, Oldenwening M, Brunekreef B, Smit HA (2013) Cohort profile: the prevention and incidence of asthma and mite allergy (PIAMA) birth cohort. Int J Epidemiol. doi:10.1093/ije/dys231